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Objective: To evaluate the antimicrobial susceptibility patterns among 469 pathogens isolated as a significant cause of 
urinary tract infections in 10 Latin American medical centers. 
Methods: Consecutively collected isolates were susceptibility tested by broth microdilution methods, and selected 
isolates were characterized by molecular typing methods. 
Results: Escherichia coli and Klebsiella spp. isolates revealed high rates of resistance to  broad-spectrum penicillins and 
t o  fluoroquinolones. Ceftazidime MlCs of s2 mg/L, suggesting the production of extended-spectrum 8-lactamases 
(ESBLs), were observed in 37.7% of K. pneumoniae and 8.3% of Escherichia col i  isolates. Enterobacterspp. isolates were 
characterized by high resistance rates to  ciprofloxacin (35%) and to  ceftazidime (45%), but they generally remained 
susceptible to  cefepime (95% susceptible). Pseudornonas aeruginosa and Acinetobacter spp. were highly resistant t o  
ciprofloxacin and ceftazidime. lmipenem was active against 80% of F! aeruginosa and 93% of Acinetobacterspp. isolates. 
Conclusions: Our results demonstrate a high level of resistance to  various classes of antimicrobial agents among 
isolates causing nosocomial urinary tract infections in Latin American hospitals. Clonal dissemination of ESBL-producing 
K. pneumoniae strains was infrequent. 
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I NTRO DU CTI 0 N 
Urinary tract infections (UTIs) are the most common 
infections occurring in hospitals and extended-care 
settings. In hospitals, approximately 80% of nosocomial 
UTIs are associated with the use of indwelling urethral 
catheters. Less than 5% of catheter-associated bac- 
teriuric patients will develop bacteremia caused by 
organisms in the urinary tract; however, because of the 
large number of catheterized patients, these bacteremias 
constitute nearly 15% of all nosocomial bloodstream 
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infections [l]. Platt et a1 demonstrated a three-fold 
increase in mortality associated with bacteriuria, even 
after a multivariate analysis excluded 20 other prospec- 
tively monitored variables [2]. In addition, catheter- 
associated bacteriuria may predispose patients to post- 
operative wound and intravenous line infections [3] .  
UTIs and other nosocomial infections have also 
become more prevalent as hospitalized patients have 
become more compromised and lengths of stay have 
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increased due to the severity of disease. In addition, 
antimicrobial resistance among pathogens causing noso- 
comial infections has increased in recent years [4]. This 
has been associated with newly recognized disease 
entities and the changing prevalence of infections due 
to significant pathogens. To address the problem of 
increasing antimicrobial resistance, surveillance pro- 
grams are necessary both locally and nationally. Several 
surveillance programs, sponsored by federal agencies or 
private resources, have been developed; but most of 
these studies have not been sufficiently comprehensive 
or international in scope [5]. Several studies of single- 
point prevalence or narrow-focus, longitudinal types 
(CDC-"IS, CDC-STD, CDC-Project ICARE, 
SCOPE, Alexander Project, etc.) have been informa- 
tive. In Brazil, several recent multicenter studies s i d a r  
to those cited have generated important data regarding 
the in vitro activity of newer 0-lactams and fluoro- 
quinolones tested against local pathogens [6,7]. 
The American Society for Microbiology Task 
Force on Antimicrobial Resistance (ASM-TFAR), 
however, suggests the necessity for a comprehensive 
longitudinal design of surveillance coupled with educa- 
tional and basic research objectives. In keeping with 
these objectives, an international surveillance study was 
launched in early 1997. This program was designated 
the SENTRY Antimicrobial Surveillance Program 
(SENTRY) and it is monitoring the frequency of occur- 
rence and antimicrobial susceptibility of pathogens 
causing infections worldwide [8,9]. In this report, we 
analyze the isolates from UTIs collected in 10 par- 
ticipant medical centers in Latin America. 
MATERIALS AND METHODS 
Organisms isolated from UTIs were collected from 
eight hospital-based laboratories and two independent 
laboratories serving various medical centers. Seven 
laboratories support tertiary hospitals while the other 
three support secondary (two laboratories) and primary 
(one laboratory) hospitals. The laboratories were 
distributed in eight cities in six Latin American 
countries. These include: SZo Paulo, Rio de Janeiro 
and Florianopolis in Brazil, Buenos Aires and San Isidro 
in Argentina, Santiago (two centers) in Chile, 
Montevideo in Uruguay Medellin in Colombia, and 
Mexico City in Mexico. 
Each participant laboratory contributed approxi- 
mately 50 isolates, consecutively collected from February 
through April, 1997. All isolates were from hospitalized 
patients, and only one isolate per patient was included. 
Four hundred and sixty-nine isolates were evaluated. 
The isolates were identified to the species level by the 
participant center and sent to the regional coordinator 
(University of Iowa, Iowa City, IA, USA) for reference 
susceptibility testing. 
Antimicrobial susceptibility testing was performed 
using the broth microdilution method as described by 
the NCCLS [lo]. Antimicrobial agents tested and 
reported here were obtained from the respective manu- 
facturers and include penicillins (penicillin, ampicillin, 
ticarcillin, piperacillin), 0-lactamase inhibitor combina- 
tions (amoxycillin-clavulanic acid, ticarcillin-clavulanic 
acid, piperacan-tazobactam), cephalosporins (cefazolin, 
cefuroxime, cefoxitin, ceftazidime, ceftriaxone, cefe- 
pime), monobactam (aztreonam), carbapenems (imi- 
penem, nieropenem), fluoroquinolones (ciprofloxacin, 
levofloxacin, ofloxacin, spadoxacin), aminoglycosides 
(amikacin, gentamicin, streptomycin, tobramycin), 
glycopeptides (vancomycin, teicoplanin), and other 
commercially available compounds, such as chloram- 
phenicol, clindamycin, doxycycline, erythromycin, 
minocycline, nitrofurantoin, rifampin, tetracycline, and 
trimethoprim-sulfamethoxazole. In addition, several 
compounds which are under investigation were also 
tested. These include fluoroquinolones (gatifloxacin 
(Bristol-Myers Squibb, Walingford, CT, USA), and 
trovafloxacin (Pfizer, Inc., Groton, CT, USA)), and 
the streptogramin quinupristin-dalfopristin (Synercid, 
Rhone-Poulenc Rorer, Collegeville, PA, USA). Quality 
control was performed by testing Esikcrichia ioli ATCC 
25932, Staphylococcus aureus ATCC 29213, Pseudomoriar 
aeruginosa ATCC 27853, and Enteroioccus faecalis ATCC 
293 12. Interpretive criteria for each antimicrobial 
tested were those recommended by the NCCLS [lo]. 
Isolates with increased MICs (2 2 mg/L) for cefta- 
zidime and/or ceftriaxone were characterized for the 
production of extended spectrum p-lactamases (ESBLs) 
and genotyped by ribotyping and pulsed-field gel 
electrophoresis (PFGE). The ESBL production was 
determined based on the susceptibility to five p-lactam 
substrates (ceftazidime. cefuroxime, cefotaxime, ceftri- 
axone, and cefepime) with and without clavulanic acid 
(fixed concentration of 2 mg/L) using Etest (AB 
Biodisk, Solna, Sweden) strips. A reduction of the p- 
lactam MIC by > 2  log2 dilutions indicated probable 
ESBL production. Strains susceptible to cephalosporins 
of the same species isolated in each medical center were 
also examined as controls. 
Ribotyping was performed using the RiboPrinter 
Microbial Characterization system (EI duPont de 
Nemours, Wilmington, DE, USA) as previously 
described [l I]. PFGE was performed using the restric- 
tion endonuclease SpeI [12,13]. Analysis of PFGE 
patterns was performed by visual inspection of photo- 
graphs of ethidium bromide-stained gels. All bands had 
to match exactly for isolates to be classified as identical. 
Banding patterns differing by one to three bands were 
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termed sirmlar and were grouped under the same DNA 
type. Isolates with greater than a three-band difference 
were considered to represent different DNA types. 
The studies of the enteric bacilli by isoelectric focus- 
ing were performed using crude p-lactamase extracts 
prepared by freeze-thaw lysis of bacterial cultures 
grown exponentially in trypic soy broth [14]. Analytic 
isoelectric focusing was performed using a Multiphore 
I1 electrophoresis system and prepared ampholine- 
polyacrylamide plates, PI 3.5-9.5 (Pharmacia Biotech, 
Uppsda, Sweden), with limits of 1500 V, 30 mA, 30 W 
for 1.5 h as per the manufacturer’s recommendations. 
Enzyme activity was detected with 0.5 mM Cefinase 2 
(Becton Dickinson Microbiology Systems, Cockeys- 
ville, MD, USA). Gels were photographed with a 
BioRad Gel Doc 1000 system fitted with a Tiffen 58 
dark green filter. P-Lactamases isolated from control 
strains (generously provided by George Jacoby) were 
used as PI standards [15]. 
RESULTS 
Gram-negative bacilli accounted for 93.6% of the 469 
isolates evaluated, while Gram-positive cocci were 
responsible for the remainder. The species dstribution 
was as follows: Escherichia coli 246 (52.5%), Klebsiella 
spp. 60 (12.8%), Pseudomonas aeruginosa 35 (7.5%), 
Proteus mirabilis 23 (4.9%). Enterobacter spp. 20 (4.3%), 
Enterococcus spp. 20 (4.3%), Acinetobacter spp. 15 (3.2%), 
staphylococci 9 (1.9%), and other Gram-negative bacilli 
40 (8.5%). 
Table 1 summarizes the susceptibility testing results 
obtained with the most frequently isolated Gram- 
negative enteric bacilli listed in the order of occurrence, 
while Table 2 shows the antimicrobial activity of 50 
non-enteric bacillus strains. Table 3 summarizes the 
susceptibility results of Enterococcus spp., the most 
prevalent Gram-positive species in UTIs. The majority 
of the isolates were Enterococcus faecalis (1 8 of 20 strains), 
and it is important to note the high prevalence of 
isolates having high-level resistance to gentamicin 
(40%) and streptomycin (50%). Only one confirmed 
Enterococcus faecalis isolate demonstrated resistance to 
vancomycin and teicoplanin (confirmed VanA pheno- 
type). Glycopeptide resistance has been uncommon in 
most South American countries. 
Table 4 shows the results of evaluating 16 K. 
pneumoniae isolates that met NCCLS screening criteria 
for increased MICs ( 2 2  mg/L) for ceftazidime and/or 
ceftriaxone. Other strains were used as test controls for 
each medical center. Based on ESBL tests using Etest 
(AB Biodisk, Solna, Sweden) strips with and without 
clavulanic acid, 12 isolates were considered to be ESBL 
producers (inhibitable enzyme, specificity of screen at 
75.0%). These 12 isolates were derived from six medical 
centers in four countries. Eleven of these isolates were 
ESBL test positive for all substrates evaluated, while one 
isolate was negative for cefuroxime and cefepime. 
Interestingly, among the 24 isolates illustrated in Table 
4, four (two ESBL positive and two ESBL negative) 
were resistant to cefoxitin (MIC 232 mg/L), indicating 
that another p-lactam resistance mechanism was 
common among K. pneumoniae isolates in Latin 
America [16,17]. A similar p-lactam resistance mech- 
anism may also be present among Escherichia coli isolates, 
since the ‘third-generation’ cephalosporins, cefiazidime 
and ceftriaxone, were more active than cefoxitin against 
this pathogen (Table 1). A total of 4.9% (ceftriaxone) 
to 8.1% (ceftazidime) of MICs for Escherichia coli were 
at or above the NCCLS screening level ( 2 2  mg/L). 
DISCUSSION 
The species distribution found in this study was similar 
to that recently reported by Weber et aJ. [l8] in a 
tertiary hospital in Israel; and it is important to note 
the increasing frequency of nosocomial UTI infections 
caused by non-enteric bacilli. The increase in the 
isolation of those pathogens contributed to the increase 
in antimicrobial resistance in organisms causing UTI 
The Enterobacteriaceae strains isolated in these Latin 
American centers showed generally high rates of 
resistance to most classes of antibiotics. More than half 
of the Escherichia coli isolates were resistant to ampicillin 
(MIC50 > 16 mg/L), ticarcdin (MICso > 128 mg/L) and 
piperacillin (MI& > 128 mg/L). The resistance rates 
were also elevated for the P-lactamase inhlbitor combin- 
ations. Amoxycillin or ticarcillin with clavulanic acid 
were active against only 59.3-59.8% of isolates (MICso 
8 mg/L), while piperaciuin-tazobactam, the most active 
compound of this antimicrobial group, was active against 
87.8% of Escherichia coli strains (MIC50 2 mg/L). The 
‘second- and third-generation’ cephalosporins, mono- 
bactam and carbapenems were active against >90% of 
tested Escherichia coli strains. Resistance to the fluoro- 
quinolones was observed for 15.4-17.1% of strains. The 
aminoglycosides were effective against many strains, 
with a rank order of amikacin (98.4% susceptible) > 
tobramycin (90.7%) > gentamicin (89.4%). 
As we expected, Escherichia coli was by far the most 
frequent pathogen isolated in the medical centers 
evaluated, and is probably the most fkequent pathogen 
causing UTIs in Latin American hospitals. The 
majority of Latin American hospitals do not routinely 
evaluate the antimicrobial susceptibility of non-repeat, 
consecutively collected UTI isolates for use in guiding 
empirical therapy. In addition, quantitative data are 
[181. 
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Table 1 Antimicrobial susceptibility of Enterobacteriaceae strains tested against 27 selected agents. 
MICs (mg/L) %by category' 
Organisms (no. tested) Antimicrobial agents 50% 90% Susceptible 
Escherichiu o l i  (246) Ampicillin 
Amoxycillin-clavulanic acid 
Ticarcillin 
Ticarcillin-clavulanic acid 
Piperacillin 
Piperacillin-tazobactam 
Cefazolin 
Cefuroxime 
Cefoxitin 
Aztreonam 
Ceftazidime 
Ceftriaxone 
Cefepime 
Imipenem 
Meropenem 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
Spadoxacin 
Trovafloxacin' 
Gatifloxacin' 
Amikacin 
Gentamicin 
Tobramycin 
Nitrofurantoin 
Tetracycline 
Trimethoprim-sulfamethoxazoieh 
Klebsiella spp.' (60) Ampicillin 
Amoxycillin-clavulanic acid 
Ticarcillin 
Ticarcillin-clavulanic acid 
Piperacillin 
Piperacillin-tazobactam 
Cefazolin 
Cefuroxime 
Cefoxitin 
Aztreonam 
Ceftazidime 
Ceftriaxone 
Cefepime 
Imipenem 
Meropenem 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
Sparfloxacin 
Trovafloxacina 
Gatifloxacma 
Amikacin 
Gentamicin 
Tobramycin 
Nitrofurantoin 
Tetracycline 
Trimethoprimsulfamethoxazole 
>16 
8 
>128 
8 
128 
2 
4 
4 
4 
10.12 
0.25 
10.25 
10.12 
0.5 
50.06 
10.015 
0.06 
10.5 
10.25 
0.06 
10.03 
4 
1 
2 
132 
54 
10.5 
>16 
16 
>I28 
32 
128 
8 
8 
8 
4 
10.12 
0.5 
10.25 
0.25 
0.5 
10.06 
0.12 
0.12 
10.5 
10.25 
0.25 
0.12 
2 
1 
1 
>64 
54 
10.5 
>16 
>16 
>128 
128 
>128 
32 
>16 
8 
8 
0.25 
0.5 
0.5 
0.5 
0.5 
10.06 
>2 
>4 
>4 
2 2  
>4 
>4 
8 
8 
4 
64 
>8 
>1 
>16 
>16 
>128 
>128 
>128 
>64 
>16 
>16 
>32 
>16 
>I6  
232 
16 
1 
0.25 
>2 
>4 
>4 
>2 
>4 
>4 
32 
>16 
>16 
>64 
28 
>1 
40.7 
59.8 
59.3 
43.5 
87.8 
74.4 
90.7 
90.2 
96.3 
97.2 
96.7 
98.4 
99.2 
99.6 
82.5 
82.5 
81.3 
82.9 
82.5 
83.7 
98.4 
89.4 
90.7 
84.1 
50.4 
43.1 
40.2 
3.3 
48.3 
3.3 
41.7 
40.0 
61.7 
53.3 
60.0 
71.7 
70.0 
71.7 
75.0 
81.7 
98.3 
98.3 
75.0 
81.7 
81.7 
75.0 
80.0 
85.0 
83.3 
71.7 
68.3 
20.0 
58.3 
53.3 
Resistant 
57.3 
16.3 
57.7 
13.8 
51.6 
8.9 
17.9 
5.7 
4.5 
3.3 
2.4 
2.4 
1.2 
0.8 
0.4 
16.3 
17.1 
15.4 
16.7 
16.7 
15.4 
0.4 
6.5 
6.5 
9.8 
49.2 
- 
93.3 
26.7 
88.3 
30.0 
53.3 
28.3 
36.7 
36.7 
15.0 
26.7 
25.0 
18.3 
1.7 
1.7 
16.7 
15.0 
16.7 
16.7 
16.7 
13.3 
8.3 
28.3 
30.0 
61.7 
40.0 
10.0 
- 
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Table 1 (Continued) 
MICs (mg/L) % by catego@ 
Organisms (no. tested) Antimicrobial agents 50% 90% Susceptible Resistant 
Profeus mirabilis (23) Ampicillin 
AmoxycJlin-clavulanic acid 
Ticarcillin 
Ticarcillin-clavulanic acid 
PiperaciLlin 
Piperacillin-tazobactam 
Cefazolin 
Cefuroxime 
Cefoxitin 
Aztreonam 
Ceftazidime 
Ceftriaxone 
Cefepime 
Imipenem 
Meropenem 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
Spadoxacin 
Trovafloxacina 
Gatifloxacin' 
Amikacin 
Gentamicin 
Tobramycin 
Nitrofurantoin 
Tetracycline 
Trimethoprimsulfamethoxazoleb 
Enterobucter spp? (20) Ampicillin 
Amoxycillin-clavulanic acid 
Ticarcillin 
Ticarcillin-clavulanic acid 
Piperacillin 
Piperacillin-tazobactam 
Cefazolin 
Cefuroxime 
Cefoxitin 
Aztreonam 
Ceftazidime 
Ceftriaxone 
Cefepime 
Imipenem 
Meropenem 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
Spadoxacin 
Trovafloxacin' 
Gatifloxacin" 
Amikacin 
Gentamicin 
Tobramycin 
Nitrofurantoin 
Tetracycline 
Trimethoprimsulfamethoxazole' 
4 
2 
51 
51 
51 
50.5 
8 
1 
4 
50.12 
50.12 
10.25 
50.12 
4 
0.25 
0.03 
0.12 
20.5 
0.5 
0.5 
0.25 
4 
2 
2 
>64 
>8 
50.5 
216 
>16 
128 
64 
32 
16 
216 
>16 
>32 
1 
2 
2 
0.5 
1 
0.12 
1 
4 
1 
1 
1 
1 
4 
1 
9 
64 
8 
>1 
>16 
216 
>128 
32 
>128 
32 
>16 
>16 
32 
>16 
>16 
32 
8 
4 
0.5 
>2 
>4 
>4 
>2 
>4 
>4 
32 
>I6  
>16 
264 
>8 
>1 
>16 
216 
>128 
2128 
>128 
>64 
>16 
>I6  
>32 
216 
>16 
>32 
8 
2 
0.5 
>2 
>4 
>4 
2 2  
24  
>4 
>32 
>16 
>16 
>64 
28 
>1 
56.5 43.5 
73.9 17.4 
56.5 34.7 
87.0 4.3 
56.5 39.1 
87.0 8.7 
65.2 30.4 
78.3 21.7 
78.3 8.7 
82.6 17.4 
87.0 13.0 
78.3 8.7 
91.3 8.7 
91.3 0.0 
100.0 0.0 
65.2 30.4 
69.6 21.7 
65.2 17.4 
60.9 38.1 
62.5 37.5 
65.2 30.4 
82.6 4.3 
73.9 26.1 
73.9 26.1 
0.0 95.7 
4.3 95.7 
56.5 - 
0.0 95.0 
5.0 95.0 
30.0 55.0 
30.0 40.0 
45.0 40.0 
65.0 35.0 
0.0 100.0 
15.0 75.0 
5.0 95.0 
60.0 40.0 
60.0 40.0 
65.0 35.0 
90.0 0.0 
100.0 0.0 
100.0 0.0 
65.0 30.0 
45.0 30.0 
65.0 35.0 
50.0 35.0 
60.0 25.0 
65.0 20.0 
80.0 15.0 
75.0 25.0 
60.0 35.0 
20.0 45.0 
40.0 50.0 
30.0 - 
"MIC results interpreted by NCCLS [8] criteria, using 2 mg/L and 8 mg/L as susceptible and resistant breakpoints, respectively, for 
investigation of fluoroquinolones. 
1/19 mg/L. 
' K .  pneumoniae (52 strains), K .  oxytom (six strains), K.  ozaenae (one strain), and Nebsiellu spp. (two strains). 
dEnterobacfer aerogenes (four strains), Enterobmfer cloacae (10 strains), Enterobacter spp. (six strains). 
0.5/9.5 mg/L as a susceptible breakpoint. The percentage of resistance was not evaluated because the highest dilution tested was only 
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Table 2 Antimicrobial susceptibility of 50 non-enteric bacillus strains tested against 1 7  selected drugs 
MICs (mg/L) % by categorya 
01-ganisms (no. tested) Antimicrobial agents 50% 90% Susceptible Resistant 
Pseudomoms aerqinosa (35) Ampicillin 
Amoxycillin-clavulanic acid 
Ticarcillin 
Ticarcilliii-clavulanic acid 
Piperacillin 
Piperacillin-tazobactam 
Cefazolin 
Cefixoxime 
Cefoxitin 
Aztreonam 
Ceftazidime 
Ceftriaxone 
Cefepime 
Imipenem 
Meropenem 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
Spadoxacin 
Trovafloxacina 
Gatifloxacid 
Amikacin 
Gentamicin 
Tobramycin 
Nitrofurantoin 
Tetracycline 
Trimethoprimmlfamethoxazole' 
.4cinetobactetev spp.' (25) Ampicillin 
Amoxycilliri-clavulanic acid 
Ticarcillin 
Ticarcillin-clavulanic acid 
Piperacillin 
Piperacillin-tazobactani 
Cefazolin 
Cefuroxime 
Cefoxitin 
Aztreonam 
Cefiazidime 
Ceftriaxone 
Cefepime 
Iinipenem 
Meropenem 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
Spadoxacin 
Trovafloxacin" 
Gatifloxacin' 
Amikacin 
Gentamicin 
Tobramycin 
Nitrofurantoin 
Tetracycline 
Trimethoprim-Sulfaniethoxazoleb 
>16 
>16 
>128 
128 
64 
32 
>16 
116  
132 
16 
8 
>32 
16 
2 
1 
> 2  
>4 
>4 
>2 
>4 
>4 
16 
>16 
>16 
>64 
>8 
>1 
>16 
> l h  
>138 
64 
>118 
64 
>16 
>16 
232 
>16 
16 
32 
>16 
0.5 
2 
> 2  
>'I 
>4 
>2 
>4 
>4 
16 
16 
8 
>64 
8 
>1 
0.0 
0.0 
40.0 
51.4 
51.4 
62.9 
0.0 
0.0 
0.0 
28.6 
54.3 
0.0 
37.1 
77.1 
82.9 
37.1 
25.7 
28.6 
22.9 
31.4 
34.3 
71.4 
25.7 
40.0 
0.0 
0.0 
0.0 
6.7 
13.3 
20.0 
20.0 
20.0 
20.0 
0.0 
0.0 
6.7 
0.0 
20.0 
13.3 
20.0 
93.3 
26.7 
26.7 
26.7 
26.7 
26.7 
26.7 
53.3 
26.7 
46.7 
0.0 
13.3 
100.0 
40.0 
483 
100.0 
100.0 
60.0 
48.6 
48.6 
37.1 
100.0 
100.0 
100.0 
45.7 
40.0 
97.1 
40.0 
14.3 
14.3 
62.9 
68.6 
68.6 
65.7 
65.7 
62.9 
28.6 
60.0 
54.3 
100.0 
94.3 
- 
86.7 
66.7 
73.4 
40.0 
80.0 
46.7 
100.0 
86.7 
93.3 
86.7 
46.7 
46.7 
66.7 
0.0 
0.0 
73.3 
73.3 
53.3 
66.7 
66.7 
66.7 
46.7 
66.7 
40.0 
86.7 
33.3 
- 
"MIC results interpreted by NCCLS [8] criteria, using 2 mg/L and 8 mg/L as susceptible and resistant breakpoints, respectively, for 
investigation of fluoroquinolones. 
'Using 0.5/9.5 mg/L as a susceptible breakpoint. The percentage of resistance was not evaluated became the highest dilution tested was only 
1/19 mg/L. 
'Includes z4, baumannii (12 strains), Acinetobacter spp. (three strains). 
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Table 3 Antimicrobial susceptibility of 20 Enterococus spp. strains tested against 23 selected agents 
~~~~ 
MICs (mg/L) % by categoe 
Orgamsms (no. tested) Anhrmcrobial agents 50% 90% Suscephble Resistant 
Enterococcus ~ p p . ~  (20) Ampicillin 
Penicillin 
Vancomycin 
Teicoplanin 
Gentamicin' 
Streptomycin' 
Amoxycdlin-clavulanic acid 
Piperacillin-tazobactam 
Imipenem 
Ceftriaxone 
Cefepime 
Ciprofloxacin 
Sparfloxacin 
Trovafloxacin' 
Gatifloxacina 
Chlorampbenicol 
Clindamycin 
Doxycycline 
Erythromycin 
Minocycline 
Nitrofurantoin 
Rifampin 
Tetracycline 
1 
2 
1 
0.25 
- 
- 
1 
4 
1 
s32 
>I6 
1 
1 
0.5 
0.5 
8 
>8 
8 
>8 
8 
232 
2 
>8 
100.0 0.0 
100.0 0.0 
95.0 5.0 
95.0 5.0 
60.0d 40.0d 
50.0d 50.0d 
100.0 0.0 
90.0 10.0 
100.0 0.0 
5.0 90.0 
10.0 80.0 
50.0 30.0 
75.0 25 .O 
70.0 10.0 
70.0 25 .o 
65.0 35.0 
0.0 95.0 
35.0 30.0 
0.0 65.0 
45.0 35.0 
80.0 5.0 
25.0 30.0 
25.0 70.0 
"MIC results interpreted by NCCLS [8] criteria, using 2 mg/L and 8 mg/L as susceptible and resistant breakpoints, respectively, for 
investigation of fluoroquinolones. 
bEnterococcusfnecalir (18 strains), Enterococcur auilrm (one strain), and Enterococclrr spp. (one strain). 
'Tested only for the presence of high-level resistance 
tests for high-level resistance. 
rarely available for analysis. Thus, the data generated in 
this study may assist in guiding empirical therapies in 
the region. The high rates of fluoroquinolone resistance 
found are of great concern since this class of antibiotic 
is heavily used to treat UTIs in several hospitals, 
although the fact that these compounds reach high 
concentrations in the lower urinary tract may prolong 
their viability as effective agents. It must be remem- 
bered however that Escherichia coli is also an important 
cause of other kind of nosocomial infections [8,9]. In 
addition to Escherichia coli, fluoroquinolone resistance 
was also high among other species, and cross-resistance 
to newer compounds was very common. The increas- 
ing fluoroquinolone resistance documented in this 
study may, due to the extensive use of fluoroquino- 
lones, ultimately jeopardize the use. of this important 
class of antibiotics in the region. However, further 
epidemiologic studies are necessary to improve our 
understanding of this problem. 
Resistance rates to (3-lactams were much higher 
among other Enterobacteriaceae isolates. Against the 
60 Klebsiella spp., piperacillin-tazobactam was active 
against 61.7% of isolates (MICso 8 mg/L), and 
ceftazidime against 71.7% (MICso 0.5 mg/L). Cefe- 
pime was the most active cephalosporin (MIC90 16 
mg/L; 81.7% susceptible) and meropenem was the 
most active compound (MIC9o 0.25 mg/L; >98% 
susceptible) overall. The fluoroquinolone compounds 
tested showed remarkably simdar activity and spectra 
(75.0-85.0%) against the Klebsiella spp. The highest 
percentage of susceptibility was demonstrated by gati- 
floxacin, while the lowest was exhibited by cipro- 
floxacin and sparfloxacin. Among Proteus mirabilis strains, 
resistance to broad-spectrum semisynthetic penicillins 
with or without an enzyme inhibitor (piperacillin 
39.1% and piperacillin-tazobactam 8.7%), to 'third- 
generation' cephalosporins (cefiazidime 13.0%) and to 
fluoroquinolones (ciprofloxacin 30.7%) was very high 
compared to North American strains Oones et al, 
unpublished data). This pattern of resistance was 
complex, and suggests ESBL and AmpC stably dere- 
pressed cephalosporinase production among these 
isolates. Co-resistance for penicillins and aminoglyco- 
sides was observed for the Proteus mirabilis strains. 
Except for the carbapenems and cefepime (no 
resistance), no other B-lactam was active against more 
than 65% of the Enterobacter spp. isolates. Rates of 
resistance to fluoroquinolones (20-35%) and to amino- 
glycosides (15-35%) were also high among isolates of 
Enterobacter spp. 
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As expected, the highest resistance rates were found 
among the non-enteric bacilli, Pseudomonas aeruginosa 
and Acinetobacter spp., pathogens that have become major 
causes of nosocomial infection in Latin American 
hospitals [8,9,19]. The carbapenems, imipenem and 
meropenem, were the most potent compounds against 
these species (Table 2). However, resistance to these 
agents has been increasing rapidly. Meropenem was 
active against 82.9% of Pseudomonas aeruginosa strains and 
93.3% of Acinetobacter spp. strains. Imipenem inhibited all 
Acinetobacter spp. strains at 5 4  mg/L and was four-fold 
more active than meropenem. Against Pseudomonas 
aeruginosa, amikacin was the next most active compound 
(following both carbapenems), with 71.4% of the isolates 
being susceptible by NCCLS [lo] criteria. Piperacillin 
was active against only 51.4% of the Pseudomonas 
aeruginosa isolates. The addition of tazobactam increased 
the susceptibility rate to 62.9%, indicating a significant 
p-lactamase component to the resistance. Ceftazidime 
inhibited 54.3% of strains at 5 8  mg/L. The percentages 
of strains (40.0%) resistant to ceftazidime and cefepime 
were identical. The most active fluoroquinolone was 
ciprofloxacin (37.1% susceptibility), but the resistance 
rates among other fluoroquinolones tested were not sig- 
nificantly different (62.948.6%). 
Recently, A. baurnannii has become a leading cause 
of nosocomial infection in several hospitals in Brazil 
[19]. In general, Acinetobacter spp. showed antimicrobial 
resistance rates higher than those demonstrated by 
Pseudomonas aeruginosa. Only the carbapenems demon- 
strated activity against more than 50% of the isolates 
(93.3-100.0% susceptibility). The next most active 
compound was amikacin (53.3% susceptibility), followed 
by tobramycin (46.7%) and the tetracyclines. Genta- 
micin and all tested fluoroquinolones were only active 
against 26.7% of the Acinetobacter spp. isolates tested 
(Table 2). Surveillance studies such as this one are 
important to help clinicians to choose empirical 
therapy for infections in which non-fermentative 
Gram-negative bacilli are a possible cause. The high 
prevalence of these pathogens, coupled with the high 
rates of resistance, has led to the increasing use of 
carbapenems in Latin America. In addition, the use of 
polimixins, which are very toxic compounds, has also 
increased in the region. 
The prevalence of ESBL-producing strains appears 
to be increasing worldwide, with great variations 
depending on the institution and the geographic area 
[20,21]. In some Latin American countries, such as 
Brazil and Argentina, the prevalence of Enterobac- 
teriaceae producing these enzymes can be as high as 
4040% of some species [22,23]. The NCCLS [lo] has 
suggested interpretive guidelines for the detection of 
Escherichia coli and K. pneumoniae isolates that could 
produce an ESBL which are based on increased MICs 
( 2 2  mg/L) for aztreonam or ceftazidime or cefpo- 
doxime or cefotaxime or ceftriaxone. Based on these 
criteria, 4.9-8.1% of Escherichia coli and 33.3-39.2% of 
K. pneumoniae UTI isolates would be considered to be 
potential ESBL producers (Tables 1 and 4). These results 
are similar to those previously reported in Brazil and 
Argentina [22,23]. 
The molecular typing results indicated that most 
UTI episodes were caused by patient-unique strains, 
although potential clonal spread of a single p-lactam- 
resistant K. pneumoniae strain was observed within one 
institution. This suggests that selection of a mutant 
subpopulation within each patient by exposure to 0- 
lactam agents was an important factor in the develop- 
ment of these resistant strains [13,16,24]. Molecular 
studies by automated ribotyping and PFGE showed 10 
and 11 different patterns, respectively, among the 12 
ESBL-positive K. pneumoniae isolates (Table 4). Two 
isolates from a single Argentine center (isolates 305 and 
326) produced an identical pattern, while all other 
isolates showed distinct PFGE patterns. Automated 
ribotyping was only slightly less discriminatory than 
PFGE. The two clonal isolates with identical PFGE 
patterns were also identical by ribotyping and both 
were resistant to cefoxitin (possibly two resistance 
mechanisms). However, another isolate from the same 
Argentine medical center (number 304), which was 
ESBL negative, had the same ribotype pattern as 
isolates 305 and 326, yet the PFGE pattern of this strain 
differed. Isoelectric focusing studies further hfferenti- 
ated the two strains that were observed to be identical 
by routine molecular epidemiology procedures (ribo- 
type 614-1; PFGE pattern A2). Each strain shared 
common PI results at 6.8 and 7.6. However, only strain 
305 produced a p-lactamase with a PI of 5.4. Isoelectric 
focusing results among ESBL-positive isolates (Table 4) 
indicate patterns consistent with TEM-1, 7 or 20, 
SHV-1, 2, 3, 5 (CAZ-4) or 6, FORM I and a unique 
pattern of a PI at 7.1 [17]. All strains with ESBL 
phenotype shared co-resistance with other anti- 
microbial classes, especially aminoglycosides, fluoro- 
quinolones, tetracyclines, and trimethoprim- 
sulfamethoxazole, was frequent among ESBL- 
producing strains isolated in South American centers 
(Table 4). The prevalence of ESBL-producing 
Enterobacteriaceae, coupled with high rates of cross- 
resistance to other antibiotic classes, has raised the use 
of carbapenems in Latin American countries, and 
contributed to increases in resistance to this potent class 
of p-lactam in the region [7,8,9,22] 
In summary, the SENTRY Antimicrobial Sur- 
veillance Program has detected high rates of antimicro- 
bial resistance among routine isolates collected from 
S a d e r  e t  a l :  A n t i m i c r o b i a l  s u s e p t i b i l i t y  o f  bacter ia  caus ing  u r i n a r y  t rac t  i n f e c t i o n s  487  
patients with UTI in Latin America, with the most 
important problems being: (1) Escherichia coli and K. 
pnenmoriiae producing ESBLs; (2) Entevobacter spp. which 
probably express chromosomally mediated (AmpC) 
stably derepressed cephalosporinases; (3)  high fluoro- 
quinolone and aminoglycoside resistance among most 
Gram-negative species; and (4) carbapenem resistance 
among Pseudomonas aeri4girzosa and Acinetobacter spp. 
Continuing surveillance of antimicrobial resistance using 
reference susceptibility testing methods and molecular 
typing will be very helpful in guiding empirical therapy 
and for the control of antimicrobial resistance at the local 
level. These data will also allow accurate comparisons 
between resistance rates in other nations worldwide. 
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